Browse Drug Recalls
17,539 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 17,539 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 17,539 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Nov 6, 2024 | Trinity Gold Nutrition, 60 Capsule, 30 day Supply, Distributed by Trinity Gol... | Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared a... | Class II | Trinity Gold Nutrition |
| Nov 6, 2024 | MAXIM Assure Antibacterial, Chloroxylenol 0.1%, Net Contents: One U.S. Gallo... | cGMP Deviations: Out of specification results for micro in hand soap products. | Class II | Midlab Incorporated |
| Nov 6, 2024 | Array Liquid Antiseptic Handwash, Chloroxylenol 0.1%, NET CONTENTS: 128 FL OZ... | cGMP Deviations: Out of specification results for micro in hand soap products. | Class II | Midlab Incorporated |
| Nov 6, 2024 | ROYALAB Germ Away Antibacterial Hand Soap, Chloroxylenol 0.1%, NET CONTENTS: ... | cGMP Deviations: Out of specification results for micro in hand soap products. | Class II | Midlab Incorporated |
| Nov 6, 2024 | BEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syr... | Lack of Sterility Assurance | Class II | Tailstorm Health INC |
| Nov 5, 2024 | Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distribu... | Failed Impurities/Degradation Specifications; during routine stability testing for impurities. | Class III | The Harvard Drug Group LLC dba Major Pharmaceut... |
| Nov 4, 2024 | ZapMax Capsules, 500 mg, 10 count blisters in cartons, Distributed by: ZapMax... | Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclof... | Class I | Boulla LLC |
| Nov 4, 2024 | VitalityXtra Capsules, 500 mg, packaged in 10 count blisters in cartons, Dist... | Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclof... | Class I | Boulla LLC |
| Nov 4, 2024 | PeakMax Capsules, 500 mg, packaged in 10 count blisters in cartons, Distribut... | Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclof... | Class I | Boulla LLC |
| Nov 4, 2024 | ZoomMax Capsules, 500 mg, 10 count blisters in cartons, Distributed by: ZoomM... | Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclof... | Class I | Boulla LLC |
| Nov 1, 2024 | Diltiazem Hydrochloride Extended-Release Capsules, USP 60 mg, Twice-a-Day Dos... | cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim... | Class II | Glenmark Pharmaceuticals Inc., USA |
| Nov 1, 2024 | Diltiazem Hydrochloride Extended-Release Capsules, USP 60 mg, Twice-a-Day Dos... | cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim... | Class II | Glenmark Pharmaceuticals Inc., USA |
| Nov 1, 2024 | Diltiazem Hydrochloride Extended-Release Capsules, USP 90 mg, Rx Only, 100 Ca... | cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim... | Class II | Glenmark Pharmaceuticals Inc., USA |
| Nov 1, 2024 | Cooling Menthol Extra Strength Pain Relief Patch, Menthol 7.5%, packaged in b... | cGMP Deviations | Class II | JR Watkins |
| Nov 1, 2024 | Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Rx Only, 100 C... | cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim... | Class II | Glenmark Pharmaceuticals Inc., USA |
| Nov 1, 2024 | Diltiazem Hydrochloride Extended-Release Capsules, USP 120mg, Twice-a-Day Dos... | cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim... | Class II | Glenmark Pharmaceuticals Inc., USA |
| Nov 1, 2024 | Diltiazem Hydrochloride Extended-Release Capsules, USP 90mg, Twice-a-Day Dosa... | cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim... | Class II | Glenmark Pharmaceuticals Inc., USA |
| Oct 31, 2024 | Xelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 ... | Defective Delivery System: The product does not meet predetermined specifications for Coldflow (a... | Class II | Noven Pharmaceuticals Inc |
| Oct 30, 2024 | Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL), 5mL Single-Dose Pre-filled S... | Labeling: Missing Label | Class II | Baxter Healthcare Corporation |
| Oct 29, 2024 | Dapsone Gel 7.5%, 60 gram pump, Rx Only, Manufactured by: Zydus Lifesciences ... | Crystallization | Class II | VIONA PHARMACEUTICALS INC |
| Oct 29, 2024 | Timolol Maleate Ophthalmic Solution USP, 0.5%, Sterile, 5mL bottles, Rx only,... | Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lod... | Class II | FDC Limited |
| Oct 29, 2024 | IBU (ibuprofen) 600 mg tablets, 500-count bottle, Rx Only, Distributor: Dr. ... | Failed Tablet/Capsule Specifications | Class III | Dr. Reddy's Laboratories, Inc. |
| Oct 25, 2024 | Lisdexamfetamine Dimesylate Capsules, 10 mg, 100 Capsules per bottle, Rx only... | Failed Content Uniformity Specifications: Product failed to meet the action limits for stratified... | Class II | Lannett Company Inc. |
| Oct 24, 2024 | THERACARE MAXIMUM STRENGTH PAIN RELIEF 4% LIDOCAINE PATCH, a) 1 patch (NDC 71... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | PARCHE LEON PAIN RELIEVING HOT PATCH, Camphor 3%, Menthol 1.25%, Capsaicin 0.... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | ABSORBINE jr. Extra Large BACK PATCH, Menthol 5%, 1 extra large patch per box... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | LILAS Feminine Pain Relief Patch, Menthol 10%, a) 5 patches per box (UPC 7 87... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | THERACARE Cold Hot Medicated Patch, Menthol 5%, 5 patches per box, Manufactur... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | EQUATE MAXIMUM STRENGTH LIDOCAINE PAIN RELIEVING PATCH Lidocaine 4% Topical A... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | ABSORBINE JR PAIN RELIEVING KNEE PATCH, Camphor 7%, Menthol 7%, packaged in a... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | HealthWise PERIOD PATCH Menstrual Pain Relief, Menthol 10%, 10 patches per bo... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | CHEEKY BONSAI PAIN RELIEF PATCHES, Menthol 10%, 4 patches per box, Distribute... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | JR WATKINS COOLING PAIN RELIEF PATCHES, Menthol 7.5%, 5 patches per box, Dist... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 24, 2024 | ABSORBINE jr ULTRA STRENGTH PAIN PATCH, Menthol 6.5%, 1 patch per box, Distri... | cGMP Deviations | Class II | Unexo Life Sciences Private Limited |
| Oct 23, 2024 | Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manuf... | Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets. | Class II | Cipla USA, Inc. |
| Oct 23, 2024 | Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manuf... | Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets. | Class II | Cipla USA, Inc. |
| Oct 23, 2024 | Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC ... | CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor | Class II | Lupin Pharmaceuticals Inc. |
| Oct 23, 2024 | Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count ND... | CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor | Class II | Lupin Pharmaceuticals Inc. |
| Oct 23, 2024 | Ramipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC... | CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor | Class II | Lupin Pharmaceuticals Inc. |
| Oct 22, 2024 | Morphine Sulfate Extended-Release Tablets 15 mg, 100-count per bottle, Rx On... | Failed Impurities/Degradation Specification | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 22, 2024 | Morphine Sulfate Extended-Release Tablets 30 mg, 100-count bottles, Rx Only,... | Failed Impurities/Degradation Specification | Class II | Dr. Reddy's Laboratories, Inc. |
| Oct 21, 2024 | Chlorpheniramine Maleate 4 mg tablets, 24-count bottle, Manufactured For: Ath... | Superpotent Drug: Stability failure for assay at 6 months test time-point. | Class II | BLI International, Inc. |
| Oct 18, 2024 | Sunitinib Malate Capsules, 12.5 mg, 28-count bottles, Rx Only, Manufactured f... | Labeling: Label Mix-Up | Class II | AvKARE |
| Oct 18, 2024 | Sunitinib Malate Capsules, 25 mg, 28-count bottles, Rx Only, Manufactured for... | Labeling: Label Mix-Up | Class II | AvKARE |
| Oct 17, 2024 | Perio Maintenance Rinse 0.63% Stannous Fluoride Concentrated Solution, Rx Onl... | Subpotent Drug | Class II | Keystone Industries |
| Oct 15, 2024 | OneLAX Docusate Sodium Liquid (docusate sodium 50 mg/5 mL) Stool Softener Lax... | CGMP Deviations | Class II | Akron Pharma, Inc. |
| Oct 11, 2024 | Triamcinolone Acetonide Cream USP, 0.025%, 1 LB (454 g) per jar, Rx Only, Man... | Subpotent and Superpotent Drug. Out of specification assay results recorded as part of Uniformity... | Class III | Padagis US LLC |
| Oct 10, 2024 | Cinacalcet Tablets, 90 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-442-... | CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptab... | Class II | ACCORD HEALTHCARE, INC. |
| Oct 10, 2024 | Cinacalcet Tablets, 60 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-441-... | CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptab... | Class II | ACCORD HEALTHCARE, INC. |
| Oct 10, 2024 | Cinacalcet Tablets 30 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-440-1... | CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptab... | Class II | ACCORD HEALTHCARE, INC. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.